On December 9, 2025, Dyne Therapeutics, Inc. announced an underwritten public offering of 18,980,478 shares of common stock at $18.44 per share, aiming to raise approximately $328.5 million. This move is expected to fund their operations through Q1 2028, relying on both offering proceeds and existing capital.